Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Attention-deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed mental health disorders and is associated with higher incidence of comorbid oppositional or conduct, mood, anxiety, pervasive developmental, and substance-use disorders. Comorbid mental health conditions may alter the presence of symptoms and treatment of ADHD. Atomoxetine (ATX), a nonstimulant medication for the treatment of ADHD, may be prescribed for individuals with ADHD and comorbid conditions despite some risk for certain undesirable side effects and lower effectiveness for the treatment of ADHD than stimulants. In this paper, we review studies utilizing randomized, placebo-controlled trials (RCTs) as well as within-subject designs to determine the effectiveness of ATX in the treatment of children and adults with ADHD and comorbid conditions. The current review uses an expanded methodology beyond systematic review of randomized controlled trials in order to improve generalizability of results to real-world practice. A total of 24 articles published from 2007 to 2015 were reviewed, including 14 RCTs: n = 1348 ATX, and n = 832 placebo. The majority of studies show that ATX is effective in the treatment of ADHD symptoms for individuals with ADHD and comorbid disorders. Cohen’s d effect sizes (ES) for improvement in ADHD symptoms and behaviors range from 0.47 to 2.21. The effectiveness of ATX to improve symptoms specific to comorbidity varied by type but appeared to be most effective for diminishing the presence of symptoms for those with comorbid anxiety, ES range of 0.40 to 1.51, and oppositional defiant disorder, ES range of 0.52 to 1.10. There are mixed or limited results for individuals with ADHD and comorbid substance-use disorders, autism spectrum disorders, dyslexia or reading disorder, depression, bipolar disorder, and Tourette syndrome. Results from this review suggest that ATX is effective in the treatment of some youth and adults with ADHD and comorbid disorders, and may be a treatment option in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity
LECKMAN, J. F., RIDDLE, M. A., HARDIN, M. T., ORT, S. I., SWARTZ, K. L., STEVENSON, J., & COHEN, D. J. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198907000-00015 · Cited by 2,146
Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder
Rommelse, N. N. J., Franke, B., Geurts, H. M., Hartman, C. A., & Buitelaar, J. K. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0092-x · Cited by 564
The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties
P, T. R. U. O. P. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00006 · Cited by 532
(2010) · PsycEXTRA Dataset · doi:10.1037/e664852010-002 · Cited by 456
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
Cited by
Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD
Myer, N. M., Boland, J. R., & Faraone, S. V. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.234 · Cited by 91
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Adult ADHD and comorbid anxiety and depressive disorders: a review of etiology and treatment
Fu, X., Wu, W., Wu, Y., Liu, X., Liang, W., Wu, R., & Li, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1597559 · Cited by 54
Mayer, J. S., Hees, K., Medda, J., Grimm, O., Asherson, P., Bellina, M., Colla, M., Ibáñez, P., Koch, E., Martinez-Nicolas, A., et al. (2018) · Trials · doi:10.1186/s13063-017-2426-1 · Cited by 48
Pharmacogenomic Biomarkers and Their Applications in Psychiatry
Kam, H., & Jeong, H. (2020) · Genes · doi:10.3390/genes11121445 · Cited by 37
“Currently, there are five ADHD medications that are approved by FDA, which can be dichotomized into stimulants (methylphenidate and amphetamine) and non-stimulants (atomoxetine, clonidine, and guanfacine) [79,80].”
Background
Metadata
- Authors
- Hutchison, S. L., Ghuman, J. K., Ghuman, H. S., Karpov, I., & Schuster, J. M.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-07-31
- Volume
- 6
- Issue
- 5
- Pages
- 317-334
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- OpenAlex
- W2396797876
- Cited by
- 41
- References
- 38
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. https://app.cochat.ai/papers/10.1177/2045125316647686
- The paper
- Hutchison, S. L., Ghuman, J. K., Ghuman, H. S., Karpov, I., & Schuster, J. M. (2016). Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125316647686
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.